The ISCBI runs informal workshops every year at different locations around the world. Previous events have been in Boston (2017), San Francisco (2016), Soeul (2016), Melbourne (June 2018) and Los Angeles (June 2019). The next meeting is in Seoul/Osong in September 2019.
We run sessions of the ISCBI workshops in coordination with various organisations and groups including ISSCR, CIRM, GAiT and Coredinate. We welcome new collaborations and support from the broadest spectrum of groups interested in stem cell applications.
ISCBI/ISCI joint meeting with Canadian Stem Cell Network
25th October 2020
3pm UK BST
The next ISCBI online session will be a joint meeting with ISCI on the 25th October that the Canadian Stem Cell Network have kindly agreed to host as a pre-conference event of the Till & McCulloch 2020 conference. Confirmed chairs include Meri Firpo, Peter Andrews, Julia Neubauer and Martin Pera. For further information and to register for this ISCI/ISCBI workshop please complete this form by Friday, October 16.
If you have any questions or would be interested to get involved in a future online session, please email firstname.lastname@example.org.
The ISCBI team
hPSC Culture and Differentiation
4th August 2020
2pm UK BST
The next ISCBI online session will take place at 2-3:45pm UK BST (6-7:45am California//9-10:45pm Singapore) on the 4th August.
The area in focus for this session is the scale up of hPSC culture and differentiation. Further detail on the session programme and speakers are given below.
Please note registration will close 24 hours before the starting time of the meeting.The registration link will be sent once registration has closed.
ISCBI session: hPSC culture and differentiation - 4th August 2pm-3.45pm BST
Dr Julia Neubauer, Fraunhofer-IBMT, Germany (session chair)
Dr Steve Oh, AStar, Singapore (session chair)
Dr Benham Baghbaderani, Lonza, USA
Prof Frank Eberhof, University of Innsbruck, Austria
Dr Micheal Peitz, University of Bonn, Germany
Information for delegates and introduction to chairs (G Stacey, ISCBI) - 1 min
Introduction to the panel (Julia Neubauer) – 1min
Dr Julia Neubauer, Fraunhofer-IBMT, Germany – 15mins
Dr Micheal Peitz, University of Bonn, Germany – 15mins
Prof Frank Eberhof, University of Innsbruck, Austria– 15mins
Dr Steve Oh, AStar, Singapore (session chair) – 15mins
Dr Benham Baghbaderani, Lonza, USA– 15mins
Q&A: review of delegates zoom-chat questions and panel responses (Chaired by J Neubauer and S Oh with G Stacey as ‘chat’ convener) – 15-30mins
Conclusion, date of next meeting, thankyou and close (G Stacey)
"New Technologies and Quality Control for Gene Edited hPSCs"
17th May 2022
Time 07.00 PST, 10.00 EST, 16.00 CET, 22.00 China-Singapore, 23.00 Korea-Japan, 00.00 Australia, 02.00 New Zealand, 15:00 BST in UK
Meeting Zoom Link:
Participants who registered for this event have been sent a zoom meeting link by email.
Please check your junk mail if you have not received the email link in your inbox.
ISCBI-COREdinates collaborative webinar 17th May
Duration: 2-2.5h session with 1.15-1.30h for short presentations and c45 min for Q&A and panel and audience discussion.
Session 1. New Developments in iPSC Technology
Chairs: Wenli Yang (U Penn. USA) and Laurence Daheron (HSCI, USA)
1. COREdinates QC survey. Wenli Yang and Laurence Daheron, COREdinates.
2. High throughput genome engineering in iPSCs, Justin McDonough, The Jackson Laboratories, USA.
3. New stem cell technologies and tools from the Allen Institute for Cell Science. Brock Roberts, Allen Institute, USA.
4. Points to consider, Quality control after single cell cloning and genome engineering, Sebastian Diecke, Max Delbruck Centre for Molecular Medicine, Germany.
Short break – 5 mins
Session 2. Quality control implementation (35-45min including Qs)
Chairs: Lyn Healy (Francis Crick Institute, UK) and Glyn Stacey (ISCBI, UK and Chinese Academy of Sciences, China)
5. Detrimental on-target effects in iPSCs, Evangelos Kiskinis, North Western University, USA.
6. Case study: Investigation and resolution of a gene editing induced APOE allele change, Benjamin Schmid, Bioneer, Denmark.
7. Cytogenetic QC at Bit.bio, Arran Constantine, BioBit (TBC).
Panel discussion with Chairs and all speakers
ISCI Genetic Stability Session
October 25th 2020
This session will be led by Prof Martin Pera
The meetings will be recorded so members who are unable to attend will be able to watch the meeting at their convenience.
Please register to attend. Meeting instructions will be sent to all registered participants.
ISCBI 2020 virtual update
As in 2019 the ISCBI annual review and Institutional updates will be made available as a virtual set of presentations for all members to review. Presentations available on request from email@example.com
We hope this will provide an ongoing resource and will promote opportunities for collaboration. The ISCBI Steering Group will be asked to select a number of updates for an on-line ISCBI session with priority given to those addressing new issues, developments of relevance to hPSC biobanking or reports from new hPSC banks. This session will be supported by an expert review panel and will run later in the summer. Sponsors are welcome to submit updates.
Special topic sessions
summer and autumn 2020
ISCBI is now setting up speaker schedules for a range of special topic sessions and ISCBI members are invited to identify their priorities
hPSCreg Development for Clinical Applications
15th July 2020
1pm UK BST
This session took place on 15th July at 1pm UK BST (9am US Western/2pm CEST/11pm Japan). The topic was the new developments for the hPSCreg database including the new clinical trial database.
Elsa Abranches, UK Stem Cell Bank, NIBSC-MHRA, UK
Rosario Isasi, University of Miami, USA
Chair: Andreas Kurtz, Berlin-Brandenburg School for Regenerative Therapies/IBMT, Germany
Nancy Mah, Berlin-Brandenburg School for Regenerative Therapies/IBMT, Germany
Convener: Glyn Stacey, ISCBI.
Instructions for delegate interaction and introduction to Chair Andreas Kurtz (G Stacey) - 2 mins
Andreas Kurtz introduction to the panel members (G Stacey) - 5 mins
Presentations introduced by Andreas Kurtz (panel members)- 40 mins
hPSCreg international perspectives, Andreas Kurtz
New hPSC-based clinical trials database and registration of hPSCs for cell therapy, Nancy Mah
Panel comments on presentations (A Kurtz) – 5 mins
Q&A: review of delegates zoom-chat questions and panel responses NB focussing on criteria for (A Kurtz) – 15mins
Conclusion and date of next meeting Review meeting concludes (G Stacey)
ISCBI review for 2019-2020 & launch of the ISCBI 2020 virtual update
ISCBI held the first of its online meetings on 1st July 2020.
This session summarised ISCBI meetings in 2019 and new working group initiatives. It also launchws the ISCBI 2020 Virtual Update session, summarising the contributions and purpose of this resource. The meeting was recorded so members who were unable to attend could watch the meeting at their convenience.
July 1st Panel:
Rosario Isasi (University of Miami)
Andreas Kurtz (Berlin-Brandenburg School for Regenerative Therapies/IBMT)
Tennielle Ludwig (WiCell)
Steve Oh (A Star)
Martin Pera (Jackson Laboratories)
Glyn Stacey (ISCBI coordinator)
Introduction to panel and instructions for delegate interaction, G Stacey
Overview of the LA and Korean meetings and new ISCBI bursaries, G Stacey, 10-15 mins
Comments from the panel on the 2019 meetings, 10mins
Summary of Virtual updates 2020, G Stacey, 5mins
Other ISCBI developments during 2019 and plans for 2020, G Stacey, 5mins
Q&A: review of delegates zoom-chat questions and panel member responses, 15mins
ISCBI June 2020 Meeting
28th June 2020
Harvard Stem Cell Institute, Boston, USA
Due to the Covid-19 coronavirus pandemic the Face to face meeting in Boston is cancelled and ISCBI will instead run on-line sessions in June-July and preliminary details will appear on the website and by email by the end of April. Dates and on-line system are being secured now and will be publicised on the website and by email to the ISCBI community.
30th June 2019, 08:00-12:30
Los Angeles, USA
ISCI Programme on Genetic Stability of Human Pluripotent Stem Cell Lines
Qualification of Raw Materials for Culture of Pluripotent Stem Cell Lines for Human Application